NeoVascularX, Inc. is a clinical-stage drug development company that exclusively licensed worldwide rights for intellectual properties (IPs) relating to AMD101 topical ophthalmic products from AMD Therapeutics LLC in Palo Alto, California, and its co-development partners. We focus on developing effective topical products for posterior eye diseases, including AMD: a leading cause of vision loss in the elderly. NeoVascularX is committed to advancing the clinical development of these products and ultimately enhancing the quality of life for individuals affected by these diseases.
At NeoVascularX, Inc., we are committed to developing innovative treatments for age-related macular degeneration. Our exclusive license for AMD101 topical ophthalmic products allows us to focus on less invasive treatments for this important disease. We believe our work will make a significantly improve vision for millions of patients affected by this condition.
The current treatments available for AMD require repeated intravitreal injections which can be daunting for many patients due to its discomfort. AMD101 topical ophthalmic products share the same approach as the established products: VEGF inhibition. However, our topical products enable AMD patients to self-administer the treatment, offering a less invasive alternative.
| Hiro Serizawa, PhD CEO |
| Dr. Serizawa has served as NVX’s Chief Executive Officer since the company was incorporated in April 2024. He is the CEO and Founder of AMD Therapeutics LLC, from which we in-licensed exclusive and worldwide rights for IPs associated with and related to NVX101 through 103. AMD101 is an active pharmaceutical ingredient in these products. He is the inventor of all patents and applications that protect the in-licensed IPs. His work regarding NVX101 through 103 started in 2014. He dedicated approximately 10 years to developing these products, resulting in outstanding achievements. He received his PhD in biochemistry from the University of Tokyo in 1991. He published numerous outstanding research papers in prominent journals. Among his publications, two original papers that were published in Nature where he was the first author have been featured in molecular biology textbooks. |
| Chief Medical Officer To be announced |
SVP of Business Deveropment To be announced |